Literature DB >> 10401633

FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier.

I Bechmann1, G Mor, J Nilsen, M Eliza, R Nitsch, F Naftolin.   

Abstract

Despite the mechanical blood-brain barrier, activated T-cells can cross brain vessels. Thus, the CNS is routinely surveyed by immune competent cells; yet the healthy brain is not a target of antigen-specific immune reactions. Therefore, mechanisms must exist to prevent brain-antigen-specific T-cells from inducing immune responses. Data indicate that activated T-cells entering the CNS may undergo apoptosis rather than leaving the brain to induce immune responses. Applying RT-PCR, Western-blots, and immunocytochemistry, we have demonstrated expression of the apoptosis-inducing protein Fas ligand on astrocytes and neurons of apparently normal rat and human brains. FasL-positive astrocytes were often situated in close vicinity to cerebral blood vessels in vivo and induced apoptosis of Fas expressing Jurkat cells in vitro. We propose that similar to other immune privileged organs FasL-induced apoptosis of activated T-cells in the brain protects the tissue from self damaging immune attacks by forming an immunological brain barrier.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401633     DOI: 10.1002/(sici)1098-1136(199907)27:1<62::aid-glia7>3.0.co;2-s

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  43 in total

1.  Genome-wide genetic associations with IFNγ response to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2012-06-03       Impact factor: 4.132

Review 2.  The adaptive immune system in diseases of the central nervous system.

Authors:  David C Wraith; Lindsay B Nicholson
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 4.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 5.  Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain.

Authors:  Burkhard Becher; Ingo Bechmann; Melanie Greter
Journal:  J Mol Med (Berl)       Date:  2006-06-14       Impact factor: 4.599

6.  Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion.

Authors:  Leman Mutlu; Christine Brandt; Erik Kwidzinski; Birgit Sawitzki; Ulrike Gimsa; Jacqueline Mahlo; Orhan Aktas; Robert Nitsch; Marloes van Zwam; Jon D Laman; Ingo Bechmann
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

Review 7.  The blood-brain barrier.

Authors:  Felix Dyrna; Sophie Hanske; Martin Krueger; Ingo Bechmann
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-06       Impact factor: 4.147

Review 8.  Immune problems in central nervous system cell therapy.

Authors:  Roger A Barker; Håkan Widner
Journal:  NeuroRx       Date:  2004-10

9.  Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS.

Authors:  Tim Magnus; Bettina Schreiner; Thomas Korn; Carolyn Jack; Hong Guo; Jack Antel; Igal Ifergan; Lieping Chen; Felix Bischof; Amit Bar-Or; Heinz Wiendl
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

Review 10.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.